
Opinion|Videos|April 2, 2024
Strategies for Preventing Progression of Early-Stage Type 1 Diabetes
Robert Gabbay, MD, PhD, discusses research showing that early intervention with a recent FDA-approved therapy can delay the onset of type 1 diabetes by an average of 2-3 years.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy
2
Linking Insured Adults to Behavioral Health Care: A Cost-Saving Solution
3
Diabetes Tied to Increased Risk of Sudden Cardiac Death
4
Evaluating Adalimumab Biosimilar Switch Impact on Disease Flares, Tolerability
5














































